ResMed (RMD) Launches Air Solutions for Improved SDB Therapy - Analyst Blog

California-based medical products manufacturer ResMed Inc. ( RMD ) recently introduced its new progressive connected care solution for treating sleep-disordered breathing (SDB) titled "Air Solutions." Management believes that this new platform will duly benefit all stakeholders involved in respiratory disorder healthcare services.

SDB, more commonly known as sleep apnea, is a common medical condition which causes one's breathing to shallow down or even stop for a few seconds or more during sleep.

Over time, ResMed has proved its mettle as a pioneer in the treatment of SDB, among other respiratory disorders. The company's top-notch customer-centric solutions have remarkably helped improve patient acceptance and adherence to SDB therapy.

The ResMed Air Solutions platform incorporates an ecosystem approach that enhances the efficacy of SDB treatment by keeping healthcare providers well informed of patients' condition. It comprises 6 data-driven units that span right from disease diagnosis to treatment, including compliance management and patient engagement.

ApneaLink Air : ResMed's compact, low-cost and lightweight type III home sleep testing device works smoothly with AirView software to provide a comprehensive diagnostic software solution for sleep labs. This device can record up to 5 channels of information: respiratory effort, pulse, oxygen saturation, nasal flow and snoring.

AirSense 10 Series : This is ResMed's brand new series of continuous and automatic positive airway pressure devices that have advanced data and communications features to upgrade the set-up, compliance management and compliance monitoring processes. This easy-to-use device platform offers a smaller bedside footprint.

AirCurve 10 Series : The AirCurve 10 series incorporates a range of adaptive-servo-ventilation (ASV) bi-level machines that provides personalized therapy to patients who suffer from central breathing disorders like Cheyne-Stokes respiration (CSR), central sleep apnea (CSA) and associated obstructive events.

AirFit Masks : Announced earlier this year, the AirFit masks are a series of light weight masks known for their easy fit and superior comfort. The AirFit line includes the AirFit P10 nasal pillows system, which is the current market leader among new patients, the AirFit F10 full-face mask and the AirFit N10 nasal mask.

AirView Monitoring and Compliance Management System : The AirView Software solution works in tandem with the Air Solutions device and can enhance patient management process by providing troubleshooting, fault detection and other functions. Airview also offers the benefit of data on demand, providing access to patient data within only an hour after the end of the therapy session.

myAir Patient Engagement Application and Software : This is an easy-to-use web application provided by ResMed, which allows patient to access their progress online. It helps them better understand their own sleep data with data dashboards, coaching and reinforcement messages.

ApneaLink Air and AirFit masks are now available in the U.S. and other select markets. The AirSense 10 and AirView will be available in the U.S. and Australia effective Aug 18, and in other markets later in 2014. The AirCurve 10 Series and myAir will also be available later in the year.

Currently, ResMed carries a Zacks Rank #4 (Sell). Other better-ranked stocks in the Medical Products industry include AtriCure, Inc. ( ATRC ), Hospira Inc. ( HSP ) and Medtronic, Inc. ( MDT ). All these stocks hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RESMED INC (RMD): Free Stock Analysis Report

MEDTRONIC (MDT): Free Stock Analysis Report

HOSPIRA INC (HSP): Free Stock Analysis Report

ATRICURE INC (ATRC): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More